stockrow
Friday 6 November 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
76.08
11.28
+17.41%
Follow CGON
Alert me
CG Oncology, Inc. (CGON) Net margin
CG Oncology, Inc.'s net margin over the twelve months to 30 September 2026 was −3,851.1%, up 133.9 percentage points from fiscal 2025 (−3,985.0%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −3,985.0% | 3,744.48 |
| FY2024 | −7,729.5% | 25,504.81 |
| FY2023 | −33,234.3% | (10,308.66) |
| FY2022 | −22,925.7% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | −3,546.8% | 3,286.02 |
| Jun 2026 | −6,832.8% | (1,274.02) |
| Mar 2026 | −5,558.8% | (3,779.79) |
| Dec 2025 | −1,779.0% | 850.50 |
| 11 more quarters | Free account |
Net margin against peers
| Company | Net margin |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 20.3% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| IMVT Immunovant, Inc. compare | 0.00% |
| MANE Veradermics Incorporated compare | 0.00% |
| SRRK Scholar Rock Holding Corporation compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| PTCT PTC Therapeutics, Inc. compare | −9.17% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −134.8% |
| CGON CG Oncology, Inc. | −3,602.7% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement